Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905172 | 0.84 | KMT2A (0.77) | EPHX2KMT2AHDAC6HDAC1HDAC2 | |
| SCHEMBL28654120 | 0.84 | SMN1; SMN2 (0.68) | EPHX2KMT2APPARGFFAR1NR1H4 | |
| SCHEMBL22987225 | 0.83 | PPARG (0.81) | EPHX2PPARGFFAR1NR1H4FFAR4 | |
| SCHEMBL28665658 | 0.82 | KMT2A (0.65) | EPHX2KMT2ANR1H4HDAC6HDAC1 | |
| SCHEMBL28656782 | 0.79 | EPHX2 (0.78) | EPHX2PPARGPPARDPPARA | |
| SCHEMBL5642848 | 0.79 | KMT2A (0.68) | EPHX2KMT2AHDAC1TTRALDH1A1 | |
| SCHEMBL22987233 | 0.78 | EPHX2 (0.69) | EPHX2PPARGFFAR1NR1H4FFAR4 | |
| SCHEMBL28926992 | 0.78 | EPHX2 (0.62) | EPHX2KMT2APPARGALDH1A1 | |
| SCHEMBL28648931 | 0.76 | KMT2A (0.65) | EPHX2KMT2ANR1H4HDAC6HDAC1 | |
| SCHEMBL22987223 | 0.76 | HPGD (0.74) | EPHX2PPARGFFAR1NR1H4FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238125-A1 | Diabetes and Metabolic Syndrome Treatment with a Novel Dual Modulator of Soluble Epoxide Hydrolase and Peroxisome Proliferator-Activated Receptors | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2021-08-05 | — | — | US | disclosed |
| US-10927069-B2 | Diabetes and metabolic syndrome treatment with a novel dual modulator of soluble epoxide hydrolase and peroxisome proliferator-activated receptors | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2021-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927069-B2 | Diabetes and metabolic syndrome treatment with a novel dual modulator of soluble epoxide hydrolase and peroxisome proliferator-activated receptors | EPHX1, EPHX2, PPARG | EPHX2 2/4885KMT2A 2564/4885PPARG 3/4885 |
| US-20210238125-A1 | Diabetes and Metabolic Syndrome Treatment with a Novel Dual Modulator of Soluble Epoxide Hydrolase and Peroxisome Proliferator-Activated Receptors | EPHX1, EPHX2, PPARG | EPHX2 2/4885KMT2A 2610/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.